TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
TransCode Therapeutics' board has initiated a formal strategic process to maximize the value of the company and its oncology portfolio, led by TTX-MC138. Options under evaluation include licensing or asset sales, development partnerships, portfolio transactions and business combinations; Tungsten Advisors has been retained as exclusive strategic financial advisor. TTX-MC138 is in Phase 2a development for ctDNA-positive colorectal cancer following curative-intent therapy, under the PRE-I-SPY program with Quantum Leap Healthcare Collaborative, and a Natera Signatera-based enrollment collaboration was announced October 13, 2026.
Key figures
- Drug Name
- TTX-MC138
- Phase Of Trial
- Phase 2a
- Phase2a trial size
- up to 45 patients
- Phase1a stable disease
- 10 of 14 efficacy-evaluable patients
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.